Dow Up0.62% Nasdaq Up0.43%




News & Info


Analyst Coverage


  • Major Holders
  • Insider Transactions
  • Insider Roster


Sun Pharma Advanced Research Company Limited (SPARC.NS)

186.80 Down 1.05(0.56%) 4:59AM EST
ProfileGet Profile for:
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Centre
Akota Road
Vadodara, 390020
India - Map

Index Membership:N/A
Industry:Drugs - Generic
Full Time Employees:318

Business Summary 

Sun Pharma Advanced Research Company Limited, a pharmaceutical company, is engaged in research and development of drugs and delivery systems. The company develops products in oncology, ophthalmology, CNS, respiratory areas. It develops Sun K706, a novel tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia; Sun 0597, a topical glucocorticoid for the treatment of allergic rhinitis, asthma, and other applications; and SUN-L731, an oral LTD4 antagonist for asthma and allergic rhinitis. The company also offers Baclofen GRS for the treatment of spasticity; Wrap Matrix controlled release systems, including Levetiracetam ER for epilepsy and Venlafaxine ER for depression; Paclitaxel injection concentrate for nanodispersion for the treatment of breast cancer; and Docetaxel injection concentrate for nanodispersion. In addition, it provides Somatostain analogues are used to treat acromegaly and growth hormone dependent cancers; BKC- free Latanoprost and Latanoprost + Timolol used for the treatment for glaucoma; and Fluticasone + Salmeterol DPI for the treatment of asthma. The company operates in India and internationally. Sun Pharma Advanced Research Company Limited is based in Vadodara, India.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Sun Pharma Advanced Research Company Limited

Key Executives 
Mr. Dilip Shantilal Shanghvi , 58
Chairman and Managing Director
Mr. Anil Raghavan ,
Chief Exec. Officer
Ms. Meetal S. Sampat , 33
Compliance Officer and Company Sec.
Dr. Subhas Bhowmick , 58
VP of R&D (Formulation)
Dr. K. Shivramchandra , 59
VP of R&D (Analytical Devel.)
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in INR.